ERD

3.3 Structural studies of PfRH5 pathway components

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

10.8 List of publications

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

1.6 Efficacy data on new antigens allowing rank ordering

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

7.7 Report on safety and immunogenicity of R21b in matrix M adjuvant

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

9.5 TB activity of TBV candidates

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

4.5 Assess immunogenicity and TBA of bivalent VLPs to select candidate for GMP manufacture

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

1.3 Generation of lead bivalent sporozoite VLP suitable for progression to GMP

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

1.4 Generation of 8 new vectored vaccine candidates

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

2.1 Liver-stage antigens identified from HLA molecules of parasitized hepatocytes

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

5.1 generation of five new VLPs with SnoopCatcher and SpyCatcher

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

7.5 Report on safety and immunogenicity of vectored prime-target immunisation in healthy volunteers

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

10.2 Establish relevant committees including PSC, PMMC, ISAC

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

1.5 Generation of 8 transgenic P berghei parasites expressing novel P falciparum antigens

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

5.2 Adequate process for lead novel VLPs for initial GMP production

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

6.4 Preclinical studies completed for adjuvant

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

4.1 Identification of new novel candidates from natural blockers and proteomic screen

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

3.4 Efficacy of new candidate blood-stage antigens

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

2.3 Rank ordering of the protective efficacy of new liver-stage antigen candidates

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

4.3 Generate VLPs for two TBV candidates and assess immunogenicity/TB

Project: OptiMalVax

Updated at: 30-10-2023

Show more information

Project acronym OptiMalVax

Periodic Reporting for period 4 - OptiMalVax (Optimizing a deployable high efficacy malaria vaccine)

Project: OptiMalVax

Updated at: 24-02-2023

Show more information

Project acronym OptiMalVax

Resources

Selected filters:

3.3 Structural studies of PfRH5 pathway components

Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies

10.8 List of publications

1.6 Efficacy data on new antigens allowing rank ordering

7.7 Report on safety and immunogenicity of R21b in matrix M adjuvant

9.5 TB activity of TBV candidates

Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine

4.5 Assess immunogenicity and TBA of bivalent VLPs to select candidate for GMP manufacture

1.3 Generation of lead bivalent sporozoite VLP suitable for progression to GMP

1.4 Generation of 8 new vectored vaccine candidates

Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates

2.1 Liver-stage antigens identified from HLA molecules of parasitized hepatocytes

5.1 generation of five new VLPs with SnoopCatcher and SpyCatcher

7.5 Report on safety and immunogenicity of vectored prime-target immunisation in healthy volunteers

10.2 Establish relevant committees including PSC, PMMC, ISAC

1.5 Generation of 8 transgenic P berghei parasites expressing novel P falciparum antigens

5.2 Adequate process for lead novel VLPs for initial GMP production

6.4 Preclinical studies completed for adjuvant

4.1 Identification of new novel candidates from natural blockers and proteomic screen

3.4 Efficacy of new candidate blood-stage antigens

2.3 Rank ordering of the protective efficacy of new liver-stage antigen candidates

4.3 Generate VLPs for two TBV candidates and assess immunogenicity/TB

Periodic Reporting for period 4 - OptiMalVax (Optimizing a deployable high efficacy malaria vaccine)